Skip to main content
SpringerLink
Log in

Serum uric acid levels in multiple sclerosis patients inversely correlate with disability

  • Brief Communication
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

Uric acid (UA) is an endogenous antioxidant. Some studies have described that multiple sclerosis (MS) patients have lower serum UA levels than controls, although it has not been established whether UA is primarily deficient, or secondarily reduced due to its scavenging activity. UA has also been proposed as an indicator of disease activity. We, retrospectively, reviewed 478 serum UA levels obtained in 94 MS patients. Ninety samples were collected during a relapse. Correlation between UA levels obtained during a relapse or in a relapse-free period, and comparison between UA and expanded disability status scale (EDSS) score was tested using a two-tailed Student’s t test and Spearman correlation coefficients test. UA levels were significantly lower when measured during a relapse (n 90) than in a remission period (n 368) (r −0.16, p 0.003) UA levels measured outside a relapse inversely correlated with EDSS score (r −0.15, p 0.001). Lower uric acid levels in MS patients are associated with clinical relapse. This is the first description of an inverse correlation of serum UA levels with disability as assessed by EDSS score.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Scott GS, Spitsin SV, Kean RB, Mikheeva T, Koprowski H, Hooper DC (2002) Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. Proc Natl Acad Sci USA 99(25):16303–16308

    Article  PubMed  CAS  Google Scholar 

  2. Touil T, Deloire-Grassin MS, Vital C, Petry KG, Brochet B (2001) In vivo damage of CNS myelin and axons induced by peroxynitrite. Neuroreport 12(16):3637–3644

    Google Scholar 

  3. Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, Chaudhry I et al (1998) Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 95(2):675–680

    Article  PubMed  CAS  Google Scholar 

  4. Toncev G, Milicic B, Toncev S, Samardzic G (2002) Serum uric acid levels in multiple sclerosis patiens correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol 9:221–226

    Article  PubMed  CAS  Google Scholar 

  5. Drulovic J, Dujmovic I, Stojsavljevic N, Mesaros S, Andjelkovic S, Miljkovic D et al (2001) Uric acid levels in sera from patients with multiple sclerosis. J Neurol 248(2):121–126

    Article  PubMed  CAS  Google Scholar 

  6. Scott GS, Hooper DC (2001) The role of uric acid in protection against peroxynitrite-mediated pathology. Med Hypotheses 56(1):95–100

    Article  PubMed  CAS  Google Scholar 

  7. Mostert JP, Ramsaransing GSM, Heersema DJ, Heerings M, Wilczak N, De Keyser J (2005) Serum uric acid levels and leukocyte nitric oxide production in multiple sclerosis patients outside relapses. J Neurol Sci 231:41–44

    Article  PubMed  CAS  Google Scholar 

  8. Karg E, Klivenyi P, Nemeth I, Bencsik K, Pinter S, Vecsei L (1999) Nonenzymatic antioxidants of blood in multiple sclerosis. J Neurol 246:533–539

    Article  PubMed  CAS  Google Scholar 

  9. Ramsaransing GSM, Heersema DJ, De Keyser J (2005) Serum uric acid, dehydroepiandrosterone sulphate, and apolipoprotein E genotype in benign vs progressive multiple sclerosis. Eur J Neurol 12:514–518

    Article  PubMed  CAS  Google Scholar 

  10. Peng F, Zhong X, Deng X, Qiu W, Wu A, Long Y et al (2010) Serum uric acid levels and neuromyelitis optica. J Neurol 257:1021–1026

    Article  PubMed  CAS  Google Scholar 

  11. Salemi G, Gueli MC, Vitale F, Battaglieri F, Guglielmini E, Ragonese P et al (2010) Blood lipids, homocysteine, stress factors, and vitamins in clinically stable multiple sclerosis patients. Lipids Health Dis 9:19–21

    Article  PubMed  Google Scholar 

  12. Massa J, O’Reilly E, Munger KL, Delorenze GN, Ascherio A (2009) Serum uric acid and risk of multiple sclerosis. J Neurol 256:1643–1648

    Article  PubMed  CAS  Google Scholar 

  13. Amorini AM, Petzold A, Tavazzi B, Eikelenboom J, Keir G, Belli A et al (2009) Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. Clin Biochem 42:1001–1006

    Article  PubMed  CAS  Google Scholar 

  14. Sotgiu S, Pugliatti M, Sanna A, Sotgiu A, Fois ML, ARRU G et al (2002) Serum uric acid and multiple sclerosis. Neurol Sci 23(4):183–188

    Article  PubMed  CAS  Google Scholar 

  15. Peng F, Zhang B, Zhong X, Li J, Xu G, Hu X et al (2008) Serum uric acid levels of patients with multiple sclerosis and other neurological diseases. Mult Scler 14:188–196

    Article  PubMed  CAS  Google Scholar 

  16. Toncev G, Milicic B, Toncev S, Samardzic G (2002) High-dose methylprednisolone theraphy in multiple sclerosis increases serum uric acid levels. Clin Chem Lab Med 40:505–508

    Article  PubMed  CAS  Google Scholar 

  17. Guerrero AL, Martín-Polo J, Laherrán E, Gutiérrez F, Iglesias F, Tejero MA et al (2008) Variation of serum uric acid levels in multiple sclerosis during relapses and immunomodulatory treatment. Eur J Neurol 15:394–397

    Article  PubMed  CAS  Google Scholar 

  18. Constantinescu CS, Freitag P, Kappos L (2000) Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with Glatiramer acetate for multiple sclerosis. Mult Scler 6:378–381

    PubMed  CAS  Google Scholar 

  19. Kanabrocki EL, Ryan MD, Hermida RC, Ayala DE, McCormick JB, Dawson S et al (2008) Uric acid and renal function in Multiple Sclerosis. Clin Ter 159:35–40

    Google Scholar 

  20. Gonsette RE, Sindic C, D′hooghe MB, De Deyn PP, Medaer R, Michotte A et al (2010) Boosting endogenous neuroprotection in multiple sclerosis: the association of inosine and interferon beta in relapsing-remitting multiple sclerosis (ASIIMS) trial. Mult Scler 16:455–462

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurology Unit, Hospital “Río Carrión”, Palencia, Spain

    A. L. Guerrero, F. Gutiérrez, F. Iglesias, J. Martín-Polo, S. Merino, J. I. Martín-Serradilla, E. Laherrán & M. A. Tejero

  2. Servicio de Neurología, Hospital Clínico Universitario de Valladolid, C/Ramón y Cajal 3, 47005, Valladolid, Spain

    A. L. Guerrero

Authors
  1. A. L. Guerrero
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Gutiérrez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Iglesias
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Martín-Polo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Merino
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. I. Martín-Serradilla
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E. Laherrán
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. A. Tejero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. L. Guerrero.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Guerrero, A.L., Gutiérrez, F., Iglesias, F. et al. Serum uric acid levels in multiple sclerosis patients inversely correlate with disability. Neurol Sci 32, 347–350 (2011). https://doi.org/10.1007/s10072-011-0488-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-011-0488-5

Keywords

Search

Navigation